What is a lyophilized peptide? Freeze-drying explained, from the three stages to the finished cake

A lyophilized peptide is a peptide that has been freeze-dried. It was dissolved, frozen solid, and then held under vacuum while the ice turned straight to vapour and the remaining bound water was driven off. What is left in the vial is a dry, porous solid called a cake. It is lighter to ship, slower to degrade and has to be dissolved again before it is used.

This guide explains the term from the ground up: what “lyophilized” means, the three stages of the process in plain language, how a lyophilized peptide compares with a liquid one, what a good cake looks like, and how a GMP fill-finish site actually makes one. For the engineering detail behind cycle design (collapse temperature, Tg′, excipients, vial choice), read our peptide lyophilization guide.

What does lyophilized mean?

Lyophilized means freeze-dried. The two terms are interchangeable: the European Commission’s GMP Annex 1 defines lyophilization as “a physical-chemical drying process designed to remove solvents, by way of sublimation, from both aqueous and non-aqueous systems, primarily to achieve product or material stability”, and adds that it “is synonymous to the term freeze-drying” [2]. The US FDA’s inspection guide puts it more simply: freeze-drying is “a process in which water is removed from a product after it is frozen” [1].

The key word is sublimation. Ice under low pressure can pass straight from solid to vapour without melting. Because the water leaves without the product ever becoming a liquid again, the peptide molecules are not exposed to a warm, concentrated solution during drying, which is what makes the method suitable for heat-sensitive molecules.

You will see two spellings. “Lyophilized” and “lyophilization” are the US forms used in most searches and in FDA documents; “lyophilised” and “lyophilisation” are the British and EMA forms. They describe the same process.

Why peptides are lyophilized

The short reason is instability in water. FDA’s guide states that “products are manufactured in the lyophilized form due to their instability when in solution” [1]. For proteins, Wang’s review of solid protein pharmaceuticals notes that they “often have to be made into solid forms to achieve an acceptable shelf life”, and that freeze-drying is the most commonly used way of doing it [8].

Synthetic peptides follow the same logic. EMA’s 2025 guideline on synthetic peptides states that “lyophilisation of synthetic peptides is considered common practice” for isolating the active substance, with precipitation, crystallisation and spray drying as alternatives [3]. After purification by reversed-phase chromatography, freeze-drying also removes volatile acids from the mobile phase: Sikora and colleagues note that the common acids, except phosphoric acid, “can be removed by lyophilization”, although trifluoroacetate can remain bound to basic residues or adsorbed in the lyophilizate [16]. That is why a certificate of analysis for a lyophilized peptide often reports counter-ion content alongside purity.

What are the three stages of lyophilization?

FDA describes freeze-drying as three interdependent stages: “freezing, primary drying (sublimation), and secondary drying (desorption)” [1]. In plain terms:

Stage	What happens	Simple analogy	What can go wrong
1. Freezing	The solution is cooled until all the water turns to ice and the peptide and excipients are concentrated in the spaces between ice crystals	Making ice cubes, but slowly and evenly	Ice structure that is too fine slows drying [7]
2. Primary drying	The chamber is put under vacuum and the shelves are warmed gently, so the ice sublimes and leaves pores behind	Frost disappearing on a cold, dry day without ever melting	If the product gets too warm, the structure softens and collapses
3. Secondary drying	The shelves are warmed further to drive off water that never froze and is bound to the solid	Drying the damp sponge left behind after the ice has gone	Too much residual water left in the cake; too fast a ramp can still cause collapse

Stage 1: freezing

The vials sit on temperature-controlled shelves inside the freeze-dryer, and the shelves are cooled until the contents are completely solid. As ice forms, the peptide and any excipients are squeezed into an increasingly concentrated, glassy or crystalline phase between the ice crystals. Kasper and Friess describe freezing as “presumably the most complex step in lyophilization”, because the size and shape of the ice crystals set the pore structure for everything that follows, including how fast the ice can later leave and how much water remains at the end [7].

For amorphous formulations, Tchessalov and colleagues’ 2023 review advises taking the shelf to −45 °C or lower so that vials at the edge of the shelf, which receive extra radiant heat, are also fully below the formulation’s glass transition [5].

Stage 2: primary drying

Once the product is frozen, the chamber pressure is pulled down and the shelves are warmed just enough to supply the energy that sublimation needs. Ice leaves from the top of the frozen plug downwards, and the vapour travels through the dried layer above it to a much colder condenser, where it refreezes.

The 2023 review reports that chamber pressure during primary drying “is almost universally maintained between 50 and 200 mTorr”, and that the target product temperature is commonly chosen as 2 °C below the formulation’s critical (collapse) temperature [5]. Primary drying is usually the longest stage: Assegehegn and colleagues call it “the longest and most critical one” of the three [6]. Running it as warm as the formulation tolerates is how cycles are shortened, which is the subject of our cycle and excipient guide.

Stage 3: secondary drying

After the ice is gone, the cake still contains water that never froze. Secondary drying removes it by desorption, mainly by raising shelf temperature; chamber pressure has little effect [5]. As a rule of thumb for typical amorphous formulations, the 2023 review reports that secondary drying “can be completed in 3–6 h at shelf temperature 40 or 50°C, with water content below 0.5 wt% commonly achieved” [5]. The same review notes that drier is not always better: some products are more stable at an intermediate water content, so the target comes from stability data [5].

At the end of the cycle, vials are normally closed inside the chamber. FDA notes that “the lyophilization process includes the stoppering of vials in the chamber” [1], usually by pressing the shelves together to seat the partially inserted stoppers.

Lyophilized vs non-lyophilized (liquid) peptides: what is the difference?

A non-lyophilized peptide is usually one supplied as a solution, ready to use. The comparison below covers the questions people ask most.

Factor	Lyophilized (freeze-dried solid)	Liquid (solution)
Chemical stability	Much slower degradation because water, the main reactant and mobility medium, is mostly removed. Solid-state deamidation, oxidation, peptide bond cleavage and aggregation still occur [9]	Faster degradation; the reason many products are made lyophilized in the first place [1]
Typical storage	Label condition from stability data; EMA notes peptides are generally stored at 5 °C ± 3 °C or −20 °C ± 5 °C [3]	Usually refrigerated or frozen, and more sensitive to excursions
Shelf life	Set by real-time stability data; for freezer-stored drug substances ICH Q1A(R2) requires real-time data at the long-term condition [17]	Generally shorter for the same peptide, again set by data
Shipping	Lighter, no liquid to spill or freeze; excursion tolerance must still be shown by data [17]	Heavier, often needs colder transport; freeze-thaw risk if shipped frozen
Handling	Must be dissolved before use; peptide powders are often very hygroscopic [3], so cold vials are best warmed before opening	Ready to use; no dissolution step
Reconstitution	Takes time and the right solvent; FDA warns that longer reconstitution “may result in partial loss of potency” [1]	Not needed
Manufacturing cost	Higher: long cycles, high energy use and heavy capital investment [15]	Lower; no freeze-drying step

The practical rule: if a peptide is stable enough in solution for the time and temperatures it will see, a liquid is simpler. If it is not, which is the usual case for research peptides held for months, the dry form wins.

Are lyophilized peptides stable?

More stable than in solution, but not permanently. Lai and Topp’s review of solid-state chemistry lists the reactions that continue in dried peptides and proteins: “deamidation, peptide bond cleavage, oxidation, the Maillard reaction, beta-elimination, and dimerization/aggregation”, influenced by “temperature, moisture content, excipients, and the physical state of the formulation (amorphous vs crystalline)” [9]. Wang’s review makes the same point for proteins: even after successful lyophilization, solid forms “may still have limited long-term storage stability” [8].

Moisture matters because water lowers the glass transition temperature of the dried solid and speeds up chemistry. In a study of a lyophilized monoclonal antibody (a protein, not a peptide, but the clearest data set), Breen and colleagues found the glass transition fell from 80 °C at 1% moisture to 25 °C at 8% moisture; high moisture decreased chemical stability, while all formulations were stable at 5 °C [10].

EMA’s peptide guideline turns this into expectations for manufacturers: peptides “are often very hygroscopic powders”, water content should be part of the stability protocol for hygroscopic material, and degradation routes to discuss include oxidation of Cys and Met, deamidation, hydrolysis and β-Asp formation [3]. For how retest dates, ICH conditions and shipping excursions are set, see lyophilized peptide stability and storage.

What should a lyophilized peptide cake look like?

The ideal is often described as “uniform and elegant”: an intact, evenly coloured, porous solid that occupies roughly the volume the liquid did. In practice, Patel and colleagues’ cross-industry commentary notes that “sometimes” a non-ideal cake appearance “has no impact on product quality and is an inherent characteristic of the product”, and proposes a harmonised nomenclature and a risk-based approach to acceptance criteria [11].

Appearance	What it is	Usual cause	Does it matter?
Intact, uniform, porous cake	The target	Product kept below its critical temperature throughout drying [4]	Expected result
Shrinkage (cake pulled away from the wall, smaller diameter)	The solid contracts during or after drying	Partly inherent: about 17% shrinkage was measured even when drying well below Tg′ and Tg in a 5% sucrose model [12]	Often cosmetic if moisture, reconstitution time and purity pass
Collapse (loss of pore structure, dense or sunken areas)	The dried matrix softens and flows	Product temperature above the collapse temperature during primary drying [5]	Can raise residual water and reconstitution time; not always harmful [13]
Meltback (glassy, bubbled or liquid-looking pocket, often at the base)	“A form of cake collapse… caused by the change from the solid to liquid state” [1]	Incomplete sublimation; ice melts before it has left	Investigate; FDA links it to changes in physical form and increased degradation [1]
Film or powder instead of a cake	Very low solid content, or a cake disturbed in transit	Small fill mass; vibration	Usually cosmetic for research material; check the mass and identity on the certificate

Two findings keep this in perspective. Exceeding the collapse temperature “would lead to less-than-elegant cake and could compromise other product quality attributes such as reconstitution time, residual water content and potency recovery”, yet several studies show collapse “does not necessarily lead to potency losses”, and microcollapse has even been associated with better long-term stability [5]. Schersch and colleagues deliberately collapsed protein cakes and found comparable residual moisture, no increase in reconstitution time and no relevant difference in protein stability versus non-collapsed cakes [13]. Appearance is a signal to look at the data, not a verdict on its own. Beyond visual inspection, development teams can use tools such as 3D laser scanning and micro-computed tomography to quantify cake structure [14].

Why a peptide cake can change after it leaves the factory

The commonest cause is moisture uptake. Because peptide powders are often very hygroscopic [3], a vial taken from a freezer and opened straight away in a warm, humid room can collect condensation, and the cake may shrink, clump or partly collapse. Letting the closed vial reach room temperature first prevents most of this. Laboratory handling after the vial is opened is covered in our guide to reconstituting lyophilized peptides in the lab.

How are lyophilized peptides made at a GMP fill-finish site?

Freeze-drying a peptide for sterile vials is part of aseptic manufacturing, not a separate drying job. Annex 1 states that lyophilization “is a critical process step and all activities that can affect the sterility of the product or material need to be regarded as extensions of the aseptic processing of the sterilised product” [2]. A typical sequence:

1. Compounding. The peptide, buffer and excipients (often a bulking agent and a lyoprotectant) are dissolved to a defined concentration.
2. Sterile filtration. Because the product cannot be sterilised in its final container, the solution is passed through “a sterile sterilising grade filter (with a nominal pore size of a maximum of 0.22 µm…)” and “subsequently aseptically filled into a previously sterilised container” [2]. FDA’s guide describes the same steps for lyophilized parenterals [1].
3. Aseptic filling and partial stoppering. Vials are filled and stoppers are seated only part way, leaving vents for vapour to escape. The transfer of partially closed containers to the freeze-dryer “should be undertaken under grade A conditions at all times” [2].
4. Loading. The loading pattern “should be specified and documented” [2]. The freeze-dryer must be sterilised on a validated schedule, and its leak rate checked “at the start of every cycle” [2].
5. The cycle. Freezing, primary drying and secondary drying run to a validated recipe developed for that formulation, vial and fill volume [4] [5].
6. Stoppering in the chamber. At the end of the cycle the stoppers are pressed home inside the chamber, under vacuum or a controlled gas [1].
7. Capping. Vials are unloaded and aluminium caps are crimped on, with the vials protected by grade A air until the cap is crimped [2].
8. Inspection and integrity. “All filled containers of parenteral products should be inspected individually” for defects, containers sealed under vacuum are tested for maintenance of vacuum, and container closure integrity validation must consider transport conditions such as “decompression or extreme temperatures” [2].
9. Release testing. Typical tests include appearance, identity, assay and purity, residual moisture, reconstitution time, and, for sterile products, sterility and endotoxin. FDA notes that “an obvious concern with the lyophilized product is the amount of moisture present in vials” [1].

Research-grade peptide isolated in a chemistry laboratory may be freeze-dried in bulk trays or flasks rather than in sterile vials, and is not made under Annex 1. The science of the three stages is the same; the controls around sterility, documentation and inspection are what differ.

Is lyophilization expensive?

Yes, compared with making a liquid. Sharma and colleagues describe batch freeze-drying as “the primary commercial means of manufacturing solid biopharmaceuticals” but also “an economically unfriendly means of production with long production cycles, high energy consumption and heavy capital investment, resulting in high overall costs” [15]. Assegehegn and colleagues similarly call it “an energy-intensive, time-consuming, and expensive process” [6], and Kasper and Friess describe it as “cost-intensive” [7].

Where the money goes:

• Time in the dryer. Cycles are long, and primary drying usually dominates [6]. Every extra hour ties up an asset that can only run one batch at a time.
• Energy. Freezing shelves, running vacuum pumps and keeping a condenser far colder than the product all consume power for the whole cycle.
• Capital and qualification. A GMP freeze-dryer needs sterilisation, leak testing and loading systems designed around grade A conditions [2].
• Development. Mapping the conditions that keep a product below its collapse temperature experimentally “would require the manufacture of multiple batches… and therefore is very expensive”, which is why computer modelling is used to reduce that cost [5].

The trade-off is usually worth it when the alternative is a solution that degrades before it can be used.

How Winhycare Pharma handles lyophilization

Winhycare Pharma offers peptide and biosimilar lyophilisation and vial filling through WHO-GMP certified manufacturing partners in India, including a standalone service for clients who bring their own peptide. Cycle development, fill-finish and release testing are scoped per molecule. See peptide lyophilisation services or send a lyophilisation enquiry. Winhycare Pharma also supplies research-use-only peptides (purity ≥99%, as stated in our brochure), which can be lyophilised and filled into vials to the customer’s configuration; see research peptides, custom peptide synthesis or send a research peptide enquiry.

For laboratory research use only. Not for human or veterinary use.